Atorvaliq (Atorvastatin Calcium) Patent Expiration, LOE Window & CMS Spending

Atorvaliq (Atorvastatin Calcium) by Cmp Development: FDA Orange Book LOE 2037-06-07, 24 AB generics, $1.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCmp Development
FDA Application & PathwayN213260 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-06-07
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors24
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$932K
2024 Medicaid Spend$294K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel